ArticleScientific reports2026
Demographic and regional disparities in concurrent respiratory and renal failure mortality: a CDC WONDER analysis, 1999-2024.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concurrent respiratory and renal failure carries exceptionally high mortality, yet population-level trends remain understudied. We analyzed temporal trends and demographic disparities in US mortality for this dual-organ failure from 1999 to 2024. We analyzed mortality data via CDC WONDER for deaths citing both respiratory (J96) and renal failure (N17-N19). Age-adjusted mortality rates (AAMRs) per 100,000 persons were extracted. Temporal trends were assessed using Joinpoint regression to estimate the Annual Percent Change (APC) with 95% confidence intervals (CIs). From 1999 to 2024, 894,269 US deaths involved concurrent respiratory and renal failure. AAMR increased from 5.76 to 14.01 per 100,000 population, rising from 1999 to 2011 (APC: 3.96), remaining stable during 2011-2018 (APC: -0.10; P = 0.90), sharply increasing during 2018-2021 (APC: 25.36), and declining from 2021 to 2024 (APC: -8.17). AAMR nearly doubled during 2020-2022 compared with 1999-2019 (16.37 vs. 8.06). Mortality was higher in men (12.01 vs. 7.66), non-Hispanic Blacks (15.42), and in the South and West, with non-metropolitan rates surpassing metropolitan areas in later years. Mortality from concurrent respiratory and renal failure more than doubled in the U.S. over the past two decades, with substantial disparities by sex, race/ethnicity, and geography. The sharp pandemic-era increase and persistent socio-regional inequities underscore a growing public health burden that warrants focused clinical attention and resource allocation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.